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Abstract  
Study question: Can asoprisnil, a selective progesterone receptor modulator, provide clinically 
meaningful improvements in heavy menstrual bleeding (HMB) associated with uterine fibroids 
with an acceptable safety profile? 
Summary answer: Uninterrupted treatment with asoprisnil for 12 months effectively controlled 
HMB and reduced fibroid and uterine volume with few adverse events. 
What is known already: In a 3-month study, asoprisnil (5, 10, and 25 mg) suppressed uterine 
bleeding, reduced fibroid and uterine volume, and improved hematological parameters in a dose-
dependent manner. 
Study design, size, duration: In two phase 3, double-blind, randomized, placebo-controlled, 
multicenter studies, women received oral asoprisnil 10 mg, asoprisnil 25 mg, or placebo (2:2:1) 
once daily for up to 12 months. 
Participants/materials, setting, methods: Premenopausal women ≥18 years of age in North 
America with HMB associated with uterine fibroids were included (N=907). The primary 
efficacy endpoint was the percentage of women who met all 3 predefined criteria at 12 months, 
or final month for subjects who prematurely discontinued: (1) ≥50% reduction in monthly blood 
loss (MBL) by menstrual pictogram, (2) hemoglobin concentration ≥11 g/dL or an increase of ≥1 
g/dL, and (3) no interventional therapy for uterine fibroids. Secondary efficacy endpoints 
included changes in other menstrual bleeding parameters, volume of the largest fibroids, uterine 
volume, and health-related quality of life (HRQL).  
Main results and the role of chance: In all, 90% and 93% of women in the asoprisnil 10 mg 
and 25 mg groups, respectively, and 35% of women in the placebo group met the primary 
endpoint (P<0.001). Similar results were observed at month 6 (P<0.001). The percentage of 
 
 
4 
 
women who achieved amenorrhea in any specified month ranged from 66% to 78% in the 
asoprisnil 10 mg group and 83% to 93% in the asoprisnil 25 mg group, significantly higher than 
with placebo (3% to 12%, P<0.001). Hemoglobin increased rapidly (by month 2) with asoprisnil 
treatment and was significantly higher versus placebo throughout treatment. The primary fibroid 
and uterine volumes were significantly reduced from baseline through month 12 with asoprisnil 
10 mg (median changes up to −48% and −28%, respectively) and 25 mg (median changes up to 
−63% and −39%, respectively) versus placebo (median changes up to +16% and +13%, 
respectively; all P<0.001). Dose-dependent, significant improvements in HRQL (Uterine Fibroid 
Symptom and Quality of Life instrument) were observed with asoprisnil treatment. Asoprisnil 
was generally well tolerated. Endometrial biopsies indicated dose- and time-dependent decreases 
in proliferative patterns and increases in quiescent or minimally stimulated endometrium at 
month 12 of treatment. Although not statistically significantly different at month 6, mean 
endometrial thickness at month 12 increased by approximately 2 mm in both asoprisnil groups 
compared with placebo (P<0.01). This effect was associated with cystic changes in the 
endometrium on MRI and ultrasonography, which led to invasive diagnostic and therapeutic 
procedures in some asoprisnil-treated women. 
Limitations, reasons for caution: Most study participants were black; few Asian and Hispanic 
women participated. The study duration may have been insufficient to fully characterize the 
endometrial effects. 
Wider implications of the findings: Daily uninterrupted treatment with asoprisnil was highly 
effective in controlling menstrual bleeding, improving anemia, reducing fibroid and uterine 
volume, and increasing HRQL in women with HMB associated with uterine fibroids. However, 
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this treatment led to an increase in endometrial thickness and invasive diagnostic and therapeutic 
procedures, with potential unknown consequences. 
Study funding/competing interest(s): AbbVie Inc. (prior sponsors: TAP Pharmaceutical 
Products Inc., Abbott Laboratories) 
Trial registration number: NCT00152269, NCT00160381 (clinicaltrials.gov) 
Trial registration date: September 7, 2005; September 8, 2005 
Date of first patient’s enrolment: September 12, 2002; September 6, 2002 
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INTRODUCTION 
Uterine fibroids (leiomyomata) are the most common neoplasms in premenopausal women. The 
cumulative incidence is approximately 80% and 70%, respectively, in black and white women, 
(Baird et al, 2003), with a two- to three-fold increased risk for development of uterine fibroids in 
black versus white women (Stewart et al, 2017). Approximately 20% to 50% of premenopausal 
women with uterine fibroids exhibit symptoms that may require clinical intervention (Buttram 
and Reiter, 1981); this includes heavy menstrual bleeding (HMB), often associated with iron-
deficiency anemia (also called abnormal uterine bleeding due to leiomyoma [AUB-L]) (Munro et 
al, 2011; Stewart, 2001) and the most common indication for hysterectomy (Carlson et al, 1993). 
 
The treatment of women with uterine fibroids is individualized based on symptoms, age, desire 
to preserve fertility, and patient preference. Hysterectomy remains the mainstay of treatment of 
symptomatic uterine fibroids in the United States, accounting for >75% of all procedures (Borah 
et al, 2016). Alternatives to hysterectomy include myomectomy, uterine artery embolization, 
magnetic resonance-guided focused ultrasound, and short-term pre-operative pharmacologic 
treatments (Stewart, 2001).  
 
Uterine fibroids respond to estradiol (E2) and progesterone (Carr et al, 1993). Newer research 
suggests that progesterone and the progesterone receptor (PR) play a more important role, 
whereas E2 has a permissive role by stimulating PR synthesis (Bulun, 2013; Chwalisz et al, 
2005b). The most compelling evidence of the role of progesterone in uterine fibroid growth and 
development comes from studies showing that selective PR modulators (SPRMs; eg, 
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mifepristone, asoprisnil, and ulipristal acetate) suppress uterine bleeding and reduce fibroid 
volume (Ali and Al-Hendy, 2017; Chwalisz et al, 2007; Donnez et al, 2012a; Eisinger et al, 
2003; Wilkens et al, 2008). Ulipristal acetate was approved initially in the EU and Canada as a 
pre-operative treatment for symptomatic uterine fibroids (Donnez et al, 2012a; Donnez et al, 
2012b), and more recently for the long-term management of symptomatic uterine fibroids using 
an intermittent treatment regimen (Donnez et al, 2014). 
 
Asoprisnil is a highly selective 11β-benzaldoxime-substituted SPRM with mixed PR 
agonist/antagonist activity (DeManno et al, 2003; Elger et al, 2000). Compared with other 
SPRMs, including mifepristone and ulipristal acetate, asoprisnil showed a higher degree of 
progesterone agonist versus antagonist activity in animal models (Elger et al, 2000). In cultured 
leiomyoma cells, asoprisnil inhibited proliferation and induced apoptosis, without similarly 
affecting myometrial cells, (Chen et al, 2006; Sasaki et al, 2007) and down-regulated collagen 
synthesis (Morikawa et al, 2008). 
 
In a phase 1 study, asoprisnil demonstrated dose-dependent suppression of menstrual bleeding 
without E2 deprivation (Chwalisz et al, 2005a). In a subsequent 3-month, phase 2 study in 
women with HMB associated with uterine fibroids, asoprisnil (5, 10, and 25 mg) suppressed 
HMB, reduced fibroid and uterine volume, improved hematological parameters in a dose-
dependent manner, and had an acceptable safety and tolerability profile (Chwalisz et al, 2007).  
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This report presents a pooled analysis of the two phase 3 studies of asoprisnil in women with 
uterine fibroids and HMB. The objective of these studies was to evaluate the safety and efficacy 
of two oral doses of asoprisnil (10 mg and 25 mg once daily) compared with placebo over a 
continuous 12-month treatment period.  
 
MATERIALS AND METHODS 
Study Design 
This report combines data from two randomized, double-blind, placebo-controlled, parallel-
group, multicenter studies (NCT00152269 [Study 1] and NCT00160381 [Study 2], 
clinicaltrials.gov) conducted in the United States and Canada between September 2002 and 
January 2005. Both studies had identical protocols except that bone mineral density (BMD) was 
evaluated in Study 1. 
 
Ethical Approval 
The studies were approved by institutional review boards and conducted in accordance with the 
Declaration of Helsinki, Good Clinical Practice Guidelines, and local and federal laws and 
regulations. An independent data safety monitoring board (DSMB) and panel of endometrial 
pathologists regularly reviewed safety.  
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Study Population 
Participants (N=907 randomized) were premenopausal women ≥18 years of age who had regular 
menstrual cycles, defined as 21 to 42 days, and agreed to use two forms of non-hormonal 
contraception throughout the studies. The presence of uterine fibroids with at least 1 of the 
following criteria was documented by ultrasound and magnetic resonance imaging (MRI): 1 
submucosal fibroid with diameter ≥2.0 cm, 1 intramural fibroid with diameter ≥3.5 cm, 1 
subserosal fibroid with diameter ≥3.5 cm, or multiple small fibroids with uterine volume ≥200 
cm3. HMB was evaluated using a validated semi-quantitative menstrual pictogram (MP) method 
(Larsen et al, 2013); eligible women had an MP score >80 mL during the screening menstrual 
cycle or hemoglobin ≤10.5 g/dL at screening and day −1 and had no evidence of malignancy or 
premalignant changes in screening endometrial biopsies and Pap smears. Study participants were 
excluded if they were pregnant, were within 3 months postpartum, used an intrauterine device, 
had a previous myomectomy within 1 year or uterine artery embolization within 6 months of 
enrollment, or had a history of polycystic ovary syndrome, prolactinomas, or malignancy, or for 
other reasons (Supplemental Methods).  
 
Efficacy Endpoints 
The primary efficacy endpoint was the proportion of women who met all of the following criteria 
at month 12 or final month for subjects who prematurely discontinued: (1) reduction from 
baseline of ≥50% in MP score, (2) hemoglobin concentration ≥11 g/dL or increase of ≥1 g/dL 
from baseline, and (3) no surgical or invasive intervention for uterine fibroids (eg, hysterectomy, 
myomectomy, and uterine artery embolism) during treatment nor withdrawal from the study with 
the intention to have such an intervention. This endpoint was designed in consultation with the 
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United States Food and Drug Administration as a surrogate measure of the avoidance of surgical 
intervention for HMB. Standardized cotton sanitary protection products (Kotex® Super and 
Nighttime napkins; Tampax® Regular, Super, and Super Plus tampons) were provided 
throughout the studies. Secondary efficacy endpoints included the response rate for the primary 
efficacy endpoint at month 6, monthly MP scores, number of days with bleeding or spotting, 
monthly rates of amenorrhea (ie, no bleeding during that month), the percentage of participants 
with suppression of menses (ie, no menses for ≥60 consecutive days during treatment after the 
end of randomization menses), maintenance of menses suppression, change from baseline in 
hemoglobin, hematocrit, ferritin, total iron binding capacity, and iron, percentage change from 
baseline in the volume of each of the two largest fibroids and the uterus at months 6 and 12, and 
the Uterine Fibroid Symptom and Quality of Life (UFS-QOL)(Spies et al, 2002) and Leiomyoma 
Symptom Assessment Questionnaire (LSAQ) (Chwalisz et al, 2007). MRI was used to measure 
fibroid and uterine volume at screening, month 6, month 12, and the month-6 follow-up visit. 
The primary fibroid was the largest fibroid based on volume. 
 
Safety Evaluation and Endpoints 
Adverse events (AEs) were recorded and evaluated throughout the studies. BMD was assessed 
(Study 1) in the lumbar spine by dual energy x-ray absorptiometry (DXA) at screening and 
month 12 in a subset of approximately 300 women. A central service (DXA Resource Group, 
Inc., Worcester, MA, USA) evaluated DXA scans. 
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Laboratory evaluations, including safety (general, hepatic, renal) and hematology parameters, 
were conducted at screening, baseline, and every 2 months during the treatment period. 
Hematology, iron, and select endocrine parameters were also collected at the follow-up month-3 
visit. Hormonal parameters (luteinizing hormone [LH], follicle-stimulating hormone [FSH], E2, 
estrone [E1], progesterone, androstenedione, total and free testosterone, sex hormone binding 
globulin [SHBG], dehydroepiandrosterone sulfate [DHEA-S], thyroid-stimulating hormone 
[TSH], thyroxine [T4], and prolactin) were measured throughout the studies (Supplemental 
Table I).  
 
Endometrial Assessments 
Each endometrial biopsy (from screening, months 6 and 12, and posttreatment month 3) was 
evaluated by two independent, central pathologists. If their diagnoses were abnormal or 
discrepant, a third central pathologist provided final arbitration. All readings were conducted 
blinded to the participant’s treatment and to the other pathologist’s diagnosis. The endometrial 
biopsy results were assessed according to diagnostic categories which were developed by the 
panel of expert endometrial pathologists specifically for asoprisnil clinical trials (Supplemental 
Methods).  
 
Saline infused sonohysterogram (SIS) was performed in participants with suspected intracavitary 
lesions on TVU or MRI images at baseline or anytime during the studies. MRI and SIS images 
were evaluated by blinded, independent central readers (WorldCare Clinical Inc., Cambridge, 
MA, USA). When indicated, hysteroscopy, dilation and curettage (D&C), and polypectomy were 
performed to evaluate imaging changes suggestive of a polyp, endometrial thickness ≥19 mm, or 
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unsatisfactory endometrial biopsies. Tissue samples obtained during these procedures were 
evaluated by both local and central pathologists. 
 
Randomization 
Eligible women (N=907) were randomized using a computer-generated randomization chart with 
a fixed block size of 5 in a 2:2:1 ratio to receive oral asoprisnil 10 mg (n=370), asoprisnil 25 mg 
(n=364), or placebo (n=173). Study drug was dispensed in blister packs, each with an attached 
blinded label. Dosing began within the first 5 days of the onset of the woman’s menstrual period 
and continued once daily for 12 months. Participants, site personnel, and sponsor remained 
blinded to treatment assignment throughout, including the posttreatment follow-up. At study 
completion, eligible women could enroll in a 12-month, open-label extension study; women who 
were ineligible or declined participation in the extension study were followed for 6 months 
thereafter to allow for the assessment of return to menses and regrowth of leiomyomata. 
Prohibited medications are listed in Supplemental Table II. Hormonal treatment before study 
initiation required predefined washout periods (2–12 months, depending on the drug). Women 
with anemia received iron supplementation to normalize hemoglobin and serum ferritin levels. 
 
Statistical Analyses 
To calculate the primary endpoint, the modified intent-to-treat (mITT) set was pre-specified in 
the statistical analysis plan. All women in the mITT set had complete baseline and treatment 
period data related to calculating the primary endpoint, and either (a) were on treatment for at 
least 30 days or (b) discontinued prior to day 30 to have surgery for fibroids. In the case of 
discontinuation to have surgery for fibroids, the woman was considered a non-responder. Pooled 
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efficacy analyses are presented for this mITT set (placebo, n=153; asoprisnil 10 mg, n=321; 
asoprisnil 25 mg, n=317). 
 
Pairwise comparisons of the primary and secondary efficacy endpoints at the participant’s final 
visit and 6 months, respectively, were performed using the Fisher exact test, using the Hochberg 
multiple comparison procedure to control the Type I error rate. Statistical methods for additional 
efficacy endpoints are noted in the Supplemental Methods. 
 
The safety population included all participants who received at least 1 dose of the study drug. 
Statistical methods for safety analyses are noted in the Supplemental Methods. Safety 
evaluations are unadjusted for multiple comparisons, and nominal P values are reported. 
 
A sample size of approximately 375 participants per study (150 participants in each of the 
asoprisnil 10- and 25-mg arms, respectively, and 75 participants in the placebo arm) would give 
90% power to detect a difference between the placebo group and asoprisnil groups assuming 
rates of 25% and 50%, respectively, for the primary endpoint based on a two-sided α=0.05 
significance level.  
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RESULTS 
Study Population 
Most participants completed the studies (73%; Figure 1). The proportions of women who 
withdrew were higher in the placebo arm (36%) than in the asoprisnil 10 mg (24%) and 25 mg 
(26%) arms. AEs were the most common reason besides “other” for discontinuation in the 
asoprisnil arms in both studies and in the placebo arm for Study 2 (Figure 1 and Supplemental 
Table III). The population in the posttreatment follow-up period included only the 238 women 
who did not enroll in the extension study. 
 
Most participants were black and were 40 years of age or older (Table I). Participant 
characteristics, fibroid-related characteristics, and hematologic parameters did not differ 
significantly between groups. Exclusion of randomized patients from primary endpoint analysis 
due to an MP score ≤80 mL and hemoglobin level >10.5 g/L during screening occurred in small 
proportions of women in the placebo (6%), asoprisnil 10-mg (5%), and asoprisnil 25-mg (4%) 
arms. 
 
Efficacy Endpoints 
In all, 90% and 93% of women in the asoprisnil 10 mg and 25 mg groups, respectively, met the 
primary efficacy endpoint compared with 35% of women in the placebo group (P<0.001; Table 
II). Similar results were observed at month 6 (P<0.001; Table II). 
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Menstrual Bleeding Parameters 
The mean monthly blood loss (MBL) was consistently and significantly (P<0.001) reduced to 
<21 mL and <13 mL by asoprisnil 10 and 25 mg, respectively, versus placebo in month 1 
through month 12 of treatment (Figure 2; Table II). There were also significant (P<0.001) 
reductions in the number of days with bleeding (Table II) and bleeding or spotting 
(Supplemental Figure 1) in both asoprisnil groups throughout treatment. Monthly amenorrhea 
rates (Figure 3) and suppression of menses rates (Table II) were significantly higher (P<0.001) 
for both asoprisnil groups. After stopping treatment, 73% to 87% and 53% to 66% of women 
treated with asoprisnil 10 mg and asoprisnil 25 mg, respectively, experienced return of menses 
within 1 month across the studies. Mean MBL during the first posttreatment menses was similar 
to baseline in both the asoprisnil 10-mg and 25-mg groups and placebo, indicating a return 
toward baseline HMB (Supplemental Table IV).  
 
Hematologic and Iron Parameters 
Hemoglobin and other hematologic parameters increased rapidly in the asoprisnil groups and 
were sustained throughout treatment. The mean increases from baseline at month 6 and month 12 
were significantly greater (P<0.001) with the asoprisnil groups compared with placebo (Table 
III and Supplemental Table V).  
 
Fibroid and Uterine Volume 
Compared with baseline, the volume of the primary fibroid was significantly reduced in women 
receiving asoprisnil (10 or 25 mg) versus placebo at 6 and 12 months (P<0.001; Figure 4); this 
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effect was maintained posttreatment. Median changes from baseline in primary fibroid volume at 
posttreatment month 6 were up to −45% with asoprisnil 10 mg and −54% with asoprisnil 25 mg 
versus up to 44% with placebo. Median changes in uterine volume were as large as −28% with 
asoprisnil 10 mg and −39% with asoprisnil 25 mg at month 6 and month 12 versus 13% with 
placebo (P<0.001). Uterine volume reductions were substantially maintained posttreatment, 
especially in the asoprisnil 25-mg group; median changes from baseline in uterine volume at 
posttreatment month 6 were up to −6% with asoprisnil 10 mg and −29% with asoprisnil 25 mg 
versus –25% to 50% with placebo. 
 
Patient-Reported Outcomes 
The UFS-QOL symptom severity score and health-related quality of life (HRQL) total score at 
month 6 and month 12 were significantly improved in women treated with asoprisnil versus 
placebo (P<0.001;Table II). All 6 HRQL subscales showed similar results (Supplemental 
Tables VI and VII). Significant improvements in bloating, pelvic pressure, and dysmenorrhea 
as measured by LSAQ were observed by month 2 for both asoprisnil groups compared with 
placebo, and these effects were maintained through month 12 (P<0.001; Supplemental Table 
VIII). 
 
Safety and Tolerability 
General Safety 
The percentage of women who reported ≥1 AE was similar among groups (Table III). Hot flush 
occurred more frequently in the asoprisnil groups and was significantly increased with the 25-mg 
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dose compared with placebo (14% vs 7%; P<0.05). Other AEs were infrequent, but bladder and 
urethral symptoms and myalgias were significantly increased with asoprisnil treatment, while 
menstrual symptoms and nonspecific muscle symptoms were decreased, compared with placebo. 
No pregnancies occurred in asoprisnil-treated women.  
Heavy menstrual bleeding (reported as uterine hemorrhage; asoprisnil 10 mg, n=1; asoprisnil 25 
mg, n=1) and cholecystitis (asoprisnil 10 mg, n=2) were the only serious AEs experienced by 
more than one woman in either study. All AEs leading to discontinuation are presented in 
Supplemental Table III. Six women discontinued because of increases in the liver enzymes 
alanine aminotransferase and/or aspartate aminotransferase (asoprisnil 10 mg, n=2 [starting days 
60 and 182]; asoprisnil 25 mg, n=3 [days 56, 61, and 63]; placebo, n=1 [day 115]), one woman 
because of an increase in gamma-glutamyl transferase (placebo [day 117]), and one woman with 
a history of Gilbert’s syndrome (asoprisnil 10 mg [day 137]) because of isolated increases in 
total bilirubin. In most women, the increases in liver enzymes were mild (2–3× the upper limit of 
normal) and transient; none of these events was associated with an increase in total bilirubin or 
symptoms. 
 
Endometrial Assessments 
Endometrial Biopsy Results 
Endometrial biopsy results are presented in Supplemental Table IX. SPRM-specific categories 
(“non-physiologic secretory effect” and “secretory pattern, mixed type”) were significantly 
increased with asoprisnil treatment at 6 and 12 months and ranged between 8% to 19% (placebo 
1%–4%), with no differences between asoprisnil doses. With asoprisnil treatment, there was a 
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dose- and time-dependent decrease in the frequency of diagnoses consistent with active 
proliferation, with “inactive” endometrium being the dominant diagnosis (28%–32%) at month 
12 of treatment, compared with placebo (3%). There were two adverse endometrial findings: one 
woman, who had a history of endometrial hyperplasia, was diagnosed with complex hyperplasia 
without atypia at the month 6 biopsy (asoprisnil 10 mg), and a second woman (asoprisnil 25 mg) 
was diagnosed with low-grade endometrial adenosarcoma in an endometrial polyp at month 9. 
Both of these changes were seen in the setting of an increase in endometrial thickness. 
Retrospective examination of the baseline MRI images of the woman with adenosarcoma did 
show a focal endometrial lesion, which suggests a potential pre-existing condition 
(Supplemental Tables X and XI). 
 
In the limited population of women who entered the posttreatment follow-up period, the 
endometrium of the vast majority of asoprisnil-treated women returned to normal cyclic 
physiologic patterns by posttreatment month 3 (Supplemental Table IX). Only 5% and 2% of 
women treated with asoprisnil at posttreatment month 3 follow-up were diagnosed with “non-
physiologic secretory effect” and “secretory pattern, mixed type,” respectively.  
 
Changes in Endometrial Thickness and Texture 
There was no significant increase in mean endometrial thickness at months 4 and 8 in both 
asoprisnil groups compared with placebo when measured with TVU (Supplemental Table X). 
However, there was slight but significant (P<0.01) increase from baseline (approximately 2 mm) 
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at month 12 in women receiving asoprisnil compared with placebo when measured with MRI 
(Supplemental Table XI).  
 
The analysis of MRI and TVU images revealed dose- and time-dependent increases in the 
percentage of women with endometrial thickness ≥19 mm at month 8 and the presence of cystic 
changes (mostly endometrial cysts and polypoid changes), which somewhat mimicked imaging 
findings of endometrial hyperplasia (Supplemental Table XII). These changes contributed to 
the notable increase in the rate of invasive diagnostic and therapeutic procedures, including 
hysteroscopy, D&C, and polypectomy, in the asoprisnil groups (7%–10%) after month 8 
compared with the placebo group (0%).  
 
Laboratory Safety Parameters 
No clinically meaningful changes in general chemistry, renal, and hepatic parameters were 
observed with asoprisnil treatment. There was little change in total cholesterol associated with 
asoprisnil treatment; however, asoprisnil significantly reduced high-density lipoprotein 
cholesterol in a dose- and time-dependent manner (Supplemental Table XIII).  
 
Endocrine and Bone Parameters 
A modest, dose-dependent inhibitory effect of asoprisnil on basal FSH and LH was observed at 
month 12 (Supplemental Table XIV). There was a dose-dependent reduction over time in E2 
(Supplemental Figure 2) and E1 in asoprisnil groups. However, most E2 levels remained in the 
early follicular phase range. Total testosterone, androstenedione, and SHBG decreased slightly 
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but significantly more from baseline with either asoprisnil dose versus placebo at 6 and 12 
months (Supplemental Table XIV). No significant differences in the mean percentage BMD 
change from baseline to month 12 were observed with asoprisnil treatment compared with 
placebo (Study 1). 
 
DISCUSSION 
In these two randomized, placebo-controlled studies, uninterrupted treatment with asoprisnil for 
12 months effectively controlled HMB, improving anemia, quality of life, and non-bleeding 
symptoms, and reducing the fibroid and uterine volumes in women with HMB and fibroids. The 
primary endpoint was achieved in ≥90% of women treated with asoprisnil versus 35% of women 
in the placebo group. The effects were rapid, dose dependent, and maintained during the entire 
treatment period, with amenorrhea rates ranging between 66% to 93% and low occurrence of 
breakthrough bleeding or spotting. The effects of asoprisnil on HMB reversed after stopping 
treatment. 
 
These results are consistent with other SPRMs, including mifepristone and ulipristal acetate 
(Donnez et al, 2012a; Donnez et al, 2014; Kettel et al, 1994; Murphy et al, 1993), and with 
earlier asoprisnil studies (Chwalisz et al, 2005a; Chwalisz et al, 2007; Wilkens et al, 2008). 
However, amenorrhea rates in the present studies seem higher than with ulipristal acetate, 
particularly in the US population (Soper et al, 2017). This increased efficacy may be related to 
our hypothesis that asoprisnil controls HMB via a dual mechanism by directly affecting the 
endometrium and indirectly inhibiting ovulation (Chwalisz et al, 2005a). Subsequent mechanistic 
 
 
21 
 
studies have suggested that the endometrial effect of asoprisnil occurs via suppression of the 
uterine NK cells that regulate the function of spiral arteries (Wilkens et al, 2013).  
 
We also observed significant, progressive reduction in fibroid and uterine volumes, with slow 
regrowth of uterine fibroids after stopping treatment, that could be due to the selective 
antiproliferative, proapoptotic effects and inhibition of extracellular matrix formation in uterine 
fibroids by asoprisnil (Morikawa et al, 2008; Ohara et al, 2007; Sasaki et al, 2007), or other 
effects including the reduction in uterine blood flow (Wilkens et al, 2008). Similarly, durable 
reduction of fibroid volume was observed after short-term treatment with ulipristal acetate 
(Donnez et al, 2014).  
 
Treatment with asoprisnil for up to 12 months was not associated with any general safety issues, 
including hepatic safety. No cases of liver injury were reported during these placebo-controlled 
studies. The small increase in the rate of hot flushes (Table III) could be attributed to the 
reduction in E2 levels. The BMD evaluation (Study 1) revealed no significant changes versus 
placebo at month 12. 
 
At no point throughout the studies did the endometrial biopsy results, which were thoroughly 
monitored by both the endometrial pathology safety panel and DSMB, raise any safety concerns. 
The endometrial effects induced by asoprisnil in endometrial biopsies were viewed as unique but 
benign changes.  
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In these studies, treatment with asoprisnil was associated with a time-dependent progression of 
endometrial changes on both endometrial biopsies and images, becoming clinically evident after 
≥8 months of treatment (Supplemental Tables X to XII), which led to an increase in diagnostic 
and therapeutic procedures. Both the endometrial biopsy results and textural change on TVU and 
MRI images seemed to reverse after stopping therapy at month 3 of the follow-up period, with 
resumption of menses. 
 
A strength of this study is the high percentage of black women, whose disease course is earlier 
and more severe compared with white women.(Baird et al, 2003; Bulun, 2013; Huyck et al, 
2008; Jacoby et al, 2010; Laughlin et al, 2010) Additionally, the HMB was severe, with mean 
and median MBL of >260 mL and approximately 200 mL, respectively. Additional strengths 
include use of validated sanitary products for bleeding assessments, thorough endometrial 
assessments involving expert endometrial pathologists, and the use of MRI to assess changes in 
fibroid and uterine volumes. A major weakness was limited follow-up data because most patients 
transferred to the open-label, uncontrolled long-term extension study, described 
separately.(Diamond et al, 2018) Additionally, hematologic analyses could be confounded by 
iron supplementation to normalize hemoglobin levels. Finally, although the current sponsor is 
committed to publication of all its interventional clinical trials conducted in patients, reports of 
these trials conducted >10 years ago had been delayed for multiple reasons including multiple 
changes in sponsor and indeterminate development plans. Despite this delay, these data are 
clinically important because they represent the only studies with an SPRM that used a continuous 
(uninterrupted) treatment regimen for 12 months. 
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In summary, asoprisnil treatment was highly effective in controlling bleeding, improving anemia, 
reducing fibroid and uterine volume, and increasing quality of life in women with HMB 
associated with uterine fibroids. The safety profile, including hepatic function, was acceptable. 
However, uninterrupted treatment with the SPRM asoprisnil may pose a safety concern because 
of the unknown long-term endometrial effects.  
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Table I. Demographics and Baseline Characteristics (All Randomized Participants) 
Characteristic Study 1 and Study 2 
(N=907) 
 Placebo 
(n=173) 
Asoprisnil 
10 mg 
(n=370) 
Asoprisnil 
25 mg 
(n=364) 
Race or ethnicity, n (%)    
Black 98 (56.6) 180 (48.6) 186 (51.1) 
White 64 (37.0) 162 (43.8) 148 (40.7) 
Hispanic 10 (5.8) 24 (6.5) 17 (4.7) 
Asian 0 2 (0.5) 6 (1.6) 
Other 1 (0.6) 2 (0.5) 7 (1.9) 
Mean (SD) age, y 42.0 (5.6) 42.8 (5.2) 43.1 (5.6) 
Mean (SD) BMI, kg/m2,a 29.9 (6.92) 29.3 (6.44) 29.4 (6.46) 
Mean (SD) primary fibroid 
volume, cm3,b 
168.7 (238.1) 189.2 (294.5) 155.2 (187.6) 
Primary fibroid location, n 
(%)b 
   
Intramural 102 (68.0) 216 (63.9) 196 (58.9) 
Pedunculated submucosal 1 (0.7) 3 (0.9) 2 (0.6) 
Pedunculated subserosal 3 (2.0) 1 (0.3) 1 (0.3) 
Submucosal 28 (18.7) 92 (27.2) 104 (31.2) 
Subserosal 16 (10.7) 26 (7.7) 30 (9.0) 
Mean (SD) uterine volume, 
cm3,c 
542.8 (430.5) 656.6 (546.6) 588.6 (454.1) 
Mean (SD) MP total score, 
mLd 
283.6 (293.3) 263.8 (213.3) 283.3 (260.4) 
Anemic, n (%)e 71 (41.5) 151 (41.7) 196 (55.1) 
Mean (SD) hemoglobin, 
g/dLe 
12.0 (1.7) 12.0 (1.8) 11.8 (1.7) 
BMI=body mass index; MP=menstrual pictogram. 
aPlacebo, n=171; asoprisnil 10 mg, n=364; asoprisnil 25 mg, n=362. 
bPlacebo, n=150; asoprisnil 10 mg, n=338; asoprisnil 25 mg, n=333. 
cAsoprisnil 10 mg, n=366; asoprisnil 25 mg, n=362. 
dPlacebo, n=171; asoprisnil 10 mg, n=363; asoprisnil 25 mg, n=359. 
ePlacebo, n=171; asoprisnil 10 mg, n=362; asoprisnil 25 mg, n=356. Hemoglobin <12 g/dL was 
considered to indicate anemia. 
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Table II. Efficacy Outcomes (mITT Population) 
 Study 1 and Study 2 
Outcome 
Placebo 
(n=153) 
Asoprisnil 10 mg 
(n=321) P Values 
Asoprisnil 25 mg 
(n=317) P Values 
 Primary endpoint response rate, n/M (%) 
Month 6 44/153 (29) 291/321 (91) <0.001a 294/315 (93) <0.001a 
Month 12 53/153 (35) 288/321 (90) <0.001a 295/317 (93) <0.001a 
 Monthly MP score: Mean change from baseline, mL (SD) 
Month 6  −112.3 (246.43) 
n=119 
−250.7 (194.97) 
n=288 
<0.001b −296.9 (265.60) 
n=283 
<0.001b 
Month 12 −106.0 (270.70) 
n=98 
−256.2 (201.62) 
n=254 
<0.001b −303.5 (284.49) 
n=233 
<0.001b 
 Number of days with bleeding: Mean change from baseline, days (SD) 
Month 6 −1.1 (3.62) 
n=119 
−6.2 (3.59) 
n=288 
<0.001b −7.0 (3.40) 
n=283 
<0.001b 
Month 12 −1.4 (3.56) 
n=97 
−6.4 (3.78) 
n=254 
<0.001b −7.0 (3.86) 
n=233 
<0.001b 
 Suppression of menses, n/M (%) 
Treatment 
period 
14/151 (9) 281/315 (89) NC 294/305 (96) NC 
 Maintenance of suppression of menses after initial suppression, n/M (%) 
Treatment 
period 
8/151 (5) 228/315 (72) NC 265/305 (87) NC 
 Hemoglobin: Mean change from baseline, g/dL (SD) 
Month 6 0.3 (1.35) 
n=109 
1.6 (1.66) 
n=259 
<0.001b 1.7 (1.63) 
n=255 
<0.001b 
Month 12 0.0 (1.40) 
n=86 
1.6 (1.72) 
n=222 
<0.001b 1.8 (1.75) 
n=214 
<0.001b 
 UFS-QoL symptom severity score: Mean change from baseline (SD) 
Month 6 −15.5 (22.47) 
n=120 
−37.0 (21.51) 
n=276 
<0.001b −46.2 (21.49) 
n=271 
<0.001b 
Month 12 −13.6 (23.91) −39.3 (19.72) <0.001b −46.9 (20.60) <0.001b 
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n=94 n=239 n=230 
 UFS-QoL HRQL total score: Mean change from baseline (SD) 
Month 6 19.8 (25.08) 
n=114 
37.6 (24.65) 
n=271 
<0.001b 44.1 (23.44) 
n=268 
<0.001b 
Month 12 13.7 (23.84) 
n=92 
39.8 (23.63) 
n=236 
<0.001b 46.5 (23.97) 
n=226 
<0.001b 
M=number of participants included in the primary endpoint analysis per given subcategory; HRQL=health-related quality of life; 
mITT=modified intent-to-treat; MP=menstrual pictogram; NC=not calculated; UFS-QoL=Uterine Fibroid Symptom and Quality of 
Life. 
aP<0.001 statistically significant difference vs placebo using the Hochberg multiple comparison procedure with an initial critical 
P=0.05 (from the Fisher exact test). 
bP<0.001 statistically significant difference vs placebo using the Hochberg multiple comparison procedure with an initial critical 
P=0.05 (from the contrasts within the framework of the analysis of covariance model with baseline as a covariate and treatment as a 
fixed factor). 
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Table III. Most Frequently Reported Adverse Events (Safety Population) 
MedDRA High-Level Term Study 1 and Study 2 
MedDRA preferred terms Placebo 
(n=173), 
n (%) 
Asoprisnil 
10 mg, 
(n=370) 
n (%) 
Asoprisnil 
25 mg, 
(n=364) 
n (%) 
Total participants with ≥1 adverse event, n (%) 145 (84) 337 (91) 321 (88) 
Upper respiratory tract infections 44 (25) 92 (25) 94 (26) 
Acute sinusitis, laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection 
Headaches NEC 44 (25) 102 (28) 92 (25) 
Headache, sinus headache, tension headache 
Musculoskeletal and connective tissue signs and 
symptoms NEC 
31 (18) 84 (23) 70 (19) 
Back pain, chest wall pain, flank pain, musculoskeletal discomfort, musculoskeletal stiffness, neck pain, nodule on 
extremity, pain in extremity, sensation of heaviness, shoulder pain 
Peripheral vascular disorders NEC 12 (7) 35 (9) 52 (14)a 
Flushing, hot flush 
Nausea and vomiting symptoms 20 (12) 48 (13) 32 (9) 
Nausea, vomiting 
Vulvovaginal signs and symptoms 16 (9) 36 (10) 39 (11) 
Genital pruritus female, postcoital bleeding, vaginal burning sensation, vaginal discharge, vaginal lesion, vaginal odour, 
vaginal pain, vulvovaginal discomfort, vulvovaginal dryness 
Breast signs and symptoms 10 (6) 39 (11) 24 (7) 
Breast discharge, breast discomfort, breast engorgement, breast pain, breast swelling, breast tenderness, nipple pain 
Gastrointestinal and abdominal pains (excluding 
oral and throat) 
15 (9) 35 (9) 39 (11) 
Abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness 
Joint-related signs and symptoms 8 (5) 29 (8) 22 (6) 
Arthralgia, joint stiffness, joint swelling, temporomandibular joint syndrome 
Fungal infections NEC 8 (5) 15 (4) 25 (7) 
Fungal infection, onychomycosis, vaginal mycosis 
Influenza viral infections 10 (6) 31 (8) 24 (7) 
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Influenza 
Menstruation and uterine bleeding NEC 12 (7) 5 (1)b 4 (1)b 
Dysmenorrhaea 
Muscle-related signs and symptoms NEC 10 (6) 8 (2)a 6 (2)a 
Muscle fatigue, muscle spasm, muscle tightness, muscle twitching 
Pain and discomfort NEC 8 (5) 25 (7) 21 (6) 
Chest pain, pain 
Bacterial infections NEC 12 (7) 20 (5) 25 (7) 
Cellulitis, upper respiratory tract infection bacterial, vaginitis bacterial 
Bladder and urethral symptoms 3 (2) 29 (8)c 23 (6)a 
Bladder spasm, dysuria, micturition urgency, pollakiuria, stress incontinence, urge incontinence, urinary incontinence 
Flatulence, bloating, and distension 5 (3) 22 (6) 23 (6) 
Abdominal distension, flatulence 
Muscle pains 3 (2) 21 (6)a 23 (6)a 
Myalgia 
Upper respiratory tract signs and symptoms 3 (2) 22 (6)a 14 (4) 
Nasal discomfort, pharyngolaryngeal pain, rhinorrhea, throat irritation, throat tightness 
Asthenic conditions 7 (4) 15 (4) 20 (5) 
Asthenia, fatigue, malaise 
Oedema NEC 9 (5) 12 (3) 9 (2) 
Generalized oedema, oedema, oedema peripheral, pitting oedema 
Reproductive tract signs and symptoms NEC 8 (5) 20 (5) 14 (4) 
Genital rash, hydrometra, pelvic pain, premenstrual syndrome 
MedDRA=Medical Dictionary for Regulatory Activities; NEC=not elsewhere classified. 
Most frequent was defined as those high-level terms reported by ≥5% of participants in any treatment group. Includes all adverse 
events from the start of the study drug through 30 days postdosing. 
aP<0.05 statistical significance vs placebo, using the Fisher exact test. 
bP<0.001 statistical significance vs placebo, using the Fisher exact test. 
cP<0.01 statistical significance vs placebo, using the Fisher exact test. 
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Figure Legends 
Figure 1. Participant flow diagram. ASO 10=asoprisnil 10 mg once daily; ASO 25=asoprisnil 25 mg once daily; PBO=placebo. 
Figure 2. Mean menstrual pictogram score in mL (modified intent-to-treat population). BL=baseline. *P<0.001 statistically 
significant difference for asoprisnil 10 mg or 25 mg vs placebo for change from baseline using the Hochberg multiple comparison 
procedure with an initial critical P=0.05 (from the Fisher exact test). Error bars represent 2 × the standard error of the mean. 
Figure 3. Percentage of women with incremental amenorrhea by month (modified intent-to-treat population). *P<0.001 statistically 
significant difference for asoprisnil 10 mg or 25 mg vs placebo using the Hochberg multiple comparison procedure with an initial 
critical P=0.05 (from the Fisher exact test). 
Figure 4. Median percentage change in volume of the largest fibroid (modified intent-to-treat population). *P<0.001 statistically 
significant difference vs placebo using the Hochberg multiple comparison procedure with an initial critical P=0.05 (from the Kruskal-
Wallis large-sample approximation test). 
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Figure 1
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Lost to follow-up: 5 (3)
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Plan to have procedure 
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Other: 10 (5)
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Protocol violation: 6 (3)
Personal reason: 7 (4)
Lost to follow-up: 4 (2)
Lack of efficacy: 0
Surgical/invasive 
intervention for uterine 
fibroids: 1 (1)
Plan to have procedure 
listed above: 2 (1)
Pregnancy: 0
Other: 9 (5)
PBO
Study 1
(N=26)
Primary Reason n (%):
Adverse event: 3 (3)
Protocol violation: 2 (2)
Personal reason: 1 (1)
Lost to follow-up: 2 (2)
Lack of efficacy: 5 (6)
Surgical/invasive 
intervention for uterine 
fibroids: 1 (1)
Plan to have procedure 
listed above: 3 (3)
Pregnancy: 1 (1)
Other: 8 (9)
Randomized
Study 2
(N=432)
86 PBO; 174 ASO 10; 172 ASO 25
Completed
Study 2
(N=301)
49 PBO; 130 ASO 10; 122 ASO 25
Prematurely Discontinued From
Treatment Period
Study 2
(N=131)
ASO 25
Study 2
(N=50)
Primary Reason n (%):
Adverse event: 13 (8)
Protocol violation: 8 (5)
Personal reason: 2 (1)
Lost to follow-up: 5 (3)
Lack of efficacy: 1 (1)
Surgical/invasive 
intervention for uterine 
fibroids: 1 (1)
Plan to have procedure 
listed above: 1 (1)
Pregnancy: 0
Other: 19 (11)
ASO 10
Study 2
(N=44)
Primary Reason n (%):
Adverse event: 12 (7)
Protocol violation: 5 (3)
Personal reason: 3 (2)
Lost to follow-up: 7 (4)
Lack of efficacy: 2 (1)
Surgical/invasive 
intervention for uterine 
fibroids: 4 (2)
Plan to have procedure 
listed above: 1 (1)
Pregnancy: 0
Other: 10 (6)
PBO
Study 2
(N=37)
Primary Reason n (%):
Adverse event: 10 (12)
Protocol violation: 2 (2)
Personal reason: 4 (5)
Lost to follow-up: 6 (7)
Lack of efficacy: 7 (8)
Surgical/invasive 
intervention for uterine 
fibroids: 0
Plan to have procedure 
listed above: 3 (3)
Pregnancy: 1 (1)
Other: 4 (5)
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Figure 2 
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Supplemental Methods 
Study Population 
Additional exclusion criteria were the presence of intracavitary pedunculated fibroids or 
endometrial polyps (assessed via saline-infusion sonohysterogram) in participants with suspected 
intracavitary lesions on transvaginal ultrasound [TVU] or MRI), hemoglobin <8 g/dL on day −1, 
and in Study 1, a bone mineral density T-score at or below −2.5 at screening. 
Endometrial Assessments 
The diagnostic dictionary included two morphologic patterns that were considered specific for 
selective progesterone receptor modulator effects. “Non-physiologic secretory pattern” referred 
to endometrial glands in which weak secretory changes were seen that were variable and 
incomplete, with basally oriented epithelial cell nuclei and minimal or no evidence of 
proliferation. “Secretory pattern – mixed type” referred to glands with non-physiological 
secretory activity as above, with additional evidence of proliferative activity (less marked basal 
orientation of epithelial cell nuclei, and more than 1 mitosis per 20 gland profiles). In both 
patterns, the stroma showed a variable degree of partial secretory differentiation. These 
categories were used in previous studies with asoprisnil (Chwalisz et al, 2005a; Chwalisz et al, 
2007; Williams et al, 2007), and were later included as part of the progesterone receptor 
modulator associated endometrial changes (PAEC) spectrum (Mutter et al, 2008). 
 
Statistical Analyses 
The mean change from baseline in monthly menstrual pictogram (MP) scores, number of days 
with bleeding, and bleeding or spotting each month were analyzed using an analysis of 
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covariance (ANCOVA) model. Changes in hemoglobin levels were analyzed using a 1-way 
ANCOVA with treatment as a factor and baseline level as a covariate. Uterine Fibroid Symptom 
and Quality of Life and Leiomyoma Symptom Assessment Questionnaire total and subscale 
scores were analyzed using the generalized Cochran-Mantel-Haenszel mean score test with 
baseline score as strata. The percentage change in fibroid and uterine volume was analyzed with 
a 1-way Kruskal-Wallis analysis with treatment as a factor; percentages of participants with 
incremental amenorrhea were compared using the Fisher exact test. Most efficacy analyses were 
based on changes from baseline to the last assessment, ie, using the last observation carried 
forward (LOCF) methodology. 
 
AEs and endometrial biopsy results for all participants were summarized by treatment group; 
pairwise between-group comparisons were performed using the Fisher exact test. Endometrial 
thickness, hematology, chemistry, urinalysis, and endocrine parameters were summarized 
descriptively; changes from baseline to each study visit were analyzed using an analysis of 
variance (ANOVA) model with treatment as a fixed factor, and pairwise comparisons were 
assessed within this model. 
 
References 
<<At submission, this section will be provided with its own bibliography.>>  
 
 
41 
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Supplemental Table XIV. Mean Hormone and SHBG at Baseline and 6 and 12 Months (All 
Participants)
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Supplemental Table I. Safety Evaluations 
Procedure/assessment  Screening Predose 
Day –1 
Months 
2 
and 4 
Month 6 Months 8 
and 10 
Month 12 Month 3  
Follow-
up 
Clinical laboratory (including 
  total iron-binding capacity) X X X X X X Xa 
Lipid profile X X — X — X — 
Endocrine panel 1b X X X X X X — 
Endocrine panel 2c X X — X — X — 
Endocrine panel 3d — — — — — — X 
Cortisol X — — — — X — 
MRI — Xe — X — X Xf 
TVU Xg — Xh — Xi — X 
BMD (Study 1 only) X — — — — X — 
Endometrial biopsy Xj — — X — X Xf 
BMD=bone mineral density; MRI=magnetic resonance imaging; TVU=transvaginal ultrasound. 
aHematology and iron assessments only. 
bEndocrine panel 1 included estrone, estradiol, androstenedione, dehydroepiandrosterone sulfate, total and free testosterone, and sex 
hormone binding globulin. 
cEndocrine panel 2 included prolactin, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, and thyroxine. 
dEndocrine panel 3 included progesterone, estradiol, total and free testosterone, and sex hormone binding globulin. 
ePerformed between day –30 and day –14. 
fPerformed at month 6 follow-up visit 
gScreening ultrasound was performed and reviewed before scheduling baseline MRI, and if needed, could have included an abdominal 
view to assess leiomyoma size and location. 
hMonth 4 only. 
iMonth 8 only. 
jScreening biopsy performed at least 21 days before day –1. 
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Supplemental Table II. Medications Not Permitted in the Studies 
 
Gonadotropin-releasing hormone agonists 
Progestogens 
Estrogens 
Oral contraceptives 
Antiestrogens 
Chronic glucocorticoids during screening, treatment, and follow-up 
Synthetic prostaglandin E1 analogs during treatment and follow-up, until cessation of the first posttreatment menses 
Cytochrome P450 3A4 inhibitors and osteoporosis treatments during treatment 
E1=estrone; GnRH=gonadotropin-releasing hormone; P450=cytochrome P450. 
Any women receiving GnRH analogs before enrollment required at least 6 months washout (9 months for 3-month depot formulations 
of leuprorelin and goserelin acetate) before treatment with asoprisnil. Participants previously receiving progesterone preparations 
required 2 months washout before treatment with asoprisnil. 
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Supplemental Table III. Adverse Events Leading to Premature Study Discontinuation (Safety Analysis Set) 
Treatment MedDRA Preferred 
Term 
Relationship to 
Study Drug (by 
Investigator) 
Severity Day of 
Onset 
Study 1 
Placebo Pain in extremity Unlikely Moderate 101 
Pain Unlikely Moderate 111 
Placebo Uterine haemorrhage Not related Severe 111 
Placebo Adnex uteri mass Unlikely Moderate 118 
Placebo Depression Possible Moderate 223 
Asoprisnil 10 mg Migraine Possible Severe 163 
Asoprisnil 10 mg Pain in extremity Possible Moderate 1, 39 
Anxiety Possible Moderate 5 
Depression Possible Moderate 5 
Insomnia Possible Moderate 5 
Pruritus Possible Mild 5 
Bursitis Not related Moderate 39 
Asoprisnil 10 mg Abdominal pain Unlikely Severe 56 
Asoprisnil 10 mg Abdominal distension Possible Moderate 82a 
Gastric disorder Possible Moderate 82a 
Asoprisnil 10 mg Stress incontinenceb Not related Severe 124 
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Asoprisnil 10 mg Migraine Possible Severe 31 
Asoprisnil 10 mg Weight increased Definite Moderate 124 
Asoprisnil 10 mg Ovarian cyst ruptured Probable Moderate 152 (0)c 
Asoprisnil 10 mg Endometrial 
hypertrophy 
Possible Moderate 136 
Asoprisnil 10 mg Malignant melanomab Not related Severe 70 
Asoprisnil 10 mg Liver function test 
abnormal 
Probable Mild 60 
Asoprisnil 10 mg Nausea Probable Severe 1 
Asoprisnil 10 mg Uterine polyp Possible Moderate 231 
Asoprisnil 10 mg Vomiting Possible Moderate 1 
Nausea Possible Moderate 1 
Asoprisnil 25 mg Bone density 
decreased 
Probable Mild 193 
Asoprisnil 25 mg Uterine leiomyomad Unlikely Moderate 187 
Asoprisnil 25 mg Acne Not related Mild 1 
Chloasma Possible Mild 63 
Asoprisnil 25 mg Hot flush Unlikely Severe 8 
Asoprisnil 25 mg Gastroenteritis viral Possible Moderate 68 
Asoprisnil 25 mg Hot flush Probable Severe 14 
Asoprisnil 25 mg Vaginal discharge Probable Mild 68 
Bone pain Possible Moderate 82 
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Headache Probable Mild 82 
Influenza like illness Possible Moderate 82 
Asoprisnil 25 mg Weight increased Possible Mild 32 
Asoprisnil 25 mg Hepatic enzyme 
increased 
Unlikely Moderate 56 
Asoprisnil 25 mg Endometrial sarcomab Probable Severe 282 
Asoprisnil 25 mg Intervertebral disc 
protrusion 
Not related Moderate 185a 
 
Study 2 
Placebo Ovarian cyst Not related Mild 128 
Placebo Libido decreased Not related Mild 49 
Weight fluctuation Not related Mild 49 
Placebo Gamma-glutamyl 
transferase increased 
Unlikely Moderate 117 
Placebo Body temperature 
increased 
Probable Mild 5 
Placebo Liver function test 
abnormal 
Probable Moderate 115 
Placebo Adnexa uteri cyst Possible Mild 186 
Placebo Abdominal pain lower Possible Severe 65 
Placebo Headache Possible Moderate 1 
 
 
48 
 
Dizziness Unlikely Mild 4 
Menorrhagia Unlikely Mild 4 
Pelvic pain Possible Moderate 4 
Syncope Unlikely Moderate 6 
Insomnia Unlikely Mild 8 
Placebo Carbohydrate antigen 
125 increased 
Not related Mild 261 
Placebo Asthmab Unlikely Severe 392 
Placebo Abdominal distension Possible Mild 98 (2)c 
Asoprisnil 10 mg Breast cancer in situ Not related Moderate 128 
Asoprisnil 10 mg Blood bilirubin 
increased 
Not related Mild 137 
Asoprisnil 10 mg Endometrial 
hyperplasia 
Possible Mild 176 
Asoprisnil 10 mg Headache Possible Moderate 69 
Paraesthesia Possible Mild 69 
Vision blurred Possible Mild 69 
Asoprisnil 10 mg Anorexia Unlikely Mild 4 
Chest discomfort Unlikely Mild 4 
Paraesthesia Unlikely Mild 4 
Asoprisnil 10 mg Headache Probable Moderatee 17, 42, 54, 
58, 60 
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Nausea Probable Moderate 17, 42, 54, 
58 
Asoprisnil 10 mg Uterine leiomyomab Not related Severe 52 (3)c 
Asoprisnil 10 mg Acne Probable Moderate 8 
Dry skin Probable Moderate 8 
Hair texture abnormal Probable Moderate 8 
Breast tenderness Probable Severe 13 
Asthenia Possible Mild 38 
Libido decreased Probable Severe 38 
Vulvovaginal dryness Probable Severe 38 
Asoprisnil 10 mg Urinary tract infection Unlikely Mild 6 
Asoprisnil 10 mg Ovarian cyst Possible Moderate 112 
Asoprisnil 10 mg Pancreatitisb Possible Severe 161 
Asoprisnil 10 mg Liver function test 
abnormal 
Possible Moderate 182 
Asoprisnil 10 mg Hypertension Unlikely Moderate 141 
Asoprisnil 25 mg Liver function test 
abnormal 
Definite Moderate 61 
Asoprisnil 25 mg Depression Probable Severe 1 
Fatigue Probable Severe 1 
Asoprisnil 25 mg Hepatic enzyme 
increased 
Probable Mild 63 
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Asoprisnil 25 mg Headache Not related Mild 1 
Asoprisnil 25 mg Endometrial disorder Possible Moderate 124 
Asoprisnil 25 mg Mood swings Definite Moderate 14 
Alopecia Definite Moderate 21 
Asoprisnil 25 mg Upper respiratory tract 
infection 
Unlikely Mild 175 
Asoprisnil 25 mg Muscle contractions 
involuntary 
Possible Mild 38 
Palpitations Possible Mild 38 
Asoprisnil 25 mg Dyspepsia Possible Mild 9 
Diarrhea Unlikely Mild 306 (1)c 
Asoprisnil 25 mg Vaginal haemorrhage Unlikely Severe 222 
Asoprisnil 25 mg Endometrial 
hyperplasia 
Probable Moderate 269 
Asoprisnil 25 mg Breast tenderness Probable Mild 261 
Asoprisnil 25 mg Fatigue Possible Moderate 162 
aEstimated. 
bSerious adverse event. 
cNumber in parentheses represents the number of days relative to the last dose of study drug. 
dDescribed as “growing fibroid.” 
eMild on day 60. 
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Supplemental Table IV. MP Score During the First Follow-Up Menses (mITT Population) 
 Study 1 Study 2 
Parameter 
Placebo 
(n=14) 
Asoprisnil 
10 mg 
(n=43) 
Asoprisnil 
25 mg 
(n=24) 
Placebo 
(n=22) 
Asoprisnil 
10 mg 
(n=29) 
Asoprisnil 
25 mg 
(n=35) 
Baseline, mean (SD) 236.0 (176.5) 191.5 (138.6) 255.1 (212.6) 265.1 
(164.0) 
191.2 (122.9) 193.4 (149.0) 
Follow-up,a mean (SD) 227.4 (460.6) 207.4 (240.6) 116.8 (183.0) 209.1 
(203.8) 
215.4 (333.8) 203.0 (361.5) 
Follow-up,a median (min, max) 102.3 (7.0, 
1815.0) 
127.0 (3.0, 
923.0) 
89.5 (3.0, 
930.0) 
188.5 (9.0, 
921.0) 
92.0 (10.0, 
1508.0) 
102.0 (7.0, 
1897.0) 
Change from baseline to follow-
up, mean (SD) 
−8.6 (467.8) 15.9 (226.0) −138.3 
(205.9) 
−56.0 
(185.1) 
24.2 (352.2) 9.6 (322.6) 
P value for change from baseline, 
asoprisnil vs placebob 
 0.978 0.182  0.509 0.601 
Max=maximum; min=minimum; mITT=modified intent to treat; MP=menstrual pictogram. 
aFollow-up menses is the first menses after the last dose. 
bP values are for pairwise comparisons from contrasts within the framework of an analysis of covariance model. 
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Supplemental Table V. Hematologic Parameters (mITT Population)  
 Study 1 and Study 2 
Parameter 
Placebo 
(n=153) 
Asoprisnil 10 mg 
(n=321) 
Asoprisnil 25 mg 
(n=317) 
Hematocrit: Mean change from baseline, % (SD) 
Month 6 0.4 (3.7) 
n=109 
2.8 (4.3)a 
n=256 
3.4 (4.1)a 
n=252 
Month 12 0.2 (3.4) 
n=86 
3.2 (4.2)a 
n=220 
3.8 (4.3)a 
n=213 
Ferritin: Mean change from baseline, ng/mL (SD) 
Month 6 0.3 (41.0) 
n=109 
20.6 (47.9)a 
n=268 
19.1 (50.7)a 
n=258 
Month 12 −4.4 (45.2) 
n=89 
28.4 (52.5)a 
n=233 
31.0 (57.9)a 
n=226 
Total iron-binding capacity: Mean change from baseline, μg/dL (SD) 
Month 6 9.8 (38.8) 
n=110 
−22.3 (39.7)a 
n=261 
−18.9 (40.1)a 
n=260 
Month 12 2.7 (38.6) 
n=89 
−35.4 (38.3)a 
n=231 
−35.5 (43.0)a 
n=227 
Iron: Mean change from baseline, μg/dL (SD) 
Month 6 15.7 (59.5) 
n=110 
34.1 (55.0)a 
n=261 
27.4 (60.6)a 
n=260 
Month 12 14.0 (56.8) 
n=89 
34.8 (51.7)a 
n=231 
25.8 (58.0)a 
n=227 
mITT=modified intent-to-treat. 
aP<0.001 statistically significant difference vs placebo using the Hochberg multiple comparison procedure with an initial critical 
P=0.05 (from the analysis of covariance model). 
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Supplemental Table VI. Change from Baseline in UFS-QoL Individual Symptom Scores (mITT Population) 
 Study 1 and Study 2 
Symptom 
Placebo 
(n=120) 
Asoprisnil 10 mg 
(n=276) 
Asoprisnil 25 mg 
(n=271) 
Heavy bleeding: Mean change from baseline 
Month 6 −0.9 
n=120 
−2.7a 
n=276 
−3.0a 
n=271 
Month 12 −0.7 
n=94 
−2.8a 
n=239 
−3.0a 
n=230 
Passing blood clots: Mean change from baseline 
Month 6 −0.9 
n=120 
−2.5a 
n=276 
−2.6a 
n=271 
Month 12 −0.6 
n=94 
−2.5a 
n=239 
−2.7a 
n=230 
Fluctuation in the duration of menstrual period: Mean change from baseline 
Month 6 −0.4 
n=119 
−1.1a 
n=275 
−1.8a 
n=271 
Month 12 −0.5 
n=93 
−1.4a 
n=238 
−1.8a 
n=230 
Fluctuation in the length of monthly cycle: Mean change from baseline 
Month 6 −0.4 
n=120 
−1.2a 
n=275 
−1.6a 
n=270 
Month 12 −0.4 
n=94 
−1.3a 
n=239 
−1.6a 
n=230 
Tightness or pressure in pelvic area: Mean change from baseline 
Month 6 −0.7 
n=118 
−1.4a 
n=275 
−1.9a 
n=270 
Month 12 −0.7 
n=92 
−1.4a 
n=239 
−1.9a 
n=229 
Frequent daytime urination: Mean change from baseline 
Month 6 −0.5 −0.9a −1.3a 
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n=120 n=275 n=269 
Month 12 −0.4 
n=92 
−0.9a 
n=239 
−1.2a 
n=228 
Frequent nighttime urination: Mean change from baseline 
Month 6 −0.4 
n=119 
−0.8a 
n=275 
−1.1a 
n=270 
Month 12 −0.4 
n=94 
−0.8a 
n=240 
−1.0a 
n=227 
Fatigue: Mean change from baseline 
Month 6 −0.8 
n=120 
−1.3a 
n=276 
−1.6a 
n=270 
Month 12 −0.7 
n=94 
−1.5a 
n=240 
−1.7a 
n=229 
mITT=modified intent-to-treat; UFS-QoL=Uterine Fibroid symptom and Health Related Quality of Life questionnaire. 
aP<0.001 statistically significant difference vs placebo analyzed using the Hochberg multiple comparison procedure with an initial 
critical P=0.05 (from the generalized Cochran-Mantel-Haenszel mean score test with baseline scores as strata). 
Score 1=Not at all; 2=A little bit; 3=Somewhat; 4=A great deal; 5=A very great deal.  
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Supplemental Table VII. Change from Baseline in UFS-QoL HRQL Subscale Scores (mITT Population)  
 Study 1 and Study 2 
Subscale 
Placebo 
(n=153) 
Asoprisnil 10 mg 
(n=321) 
Asoprisnil 25 mg 
(n=317) 
Concern: Mean change from baseline (SD) 
Month 6 21.3 (30.2) 
n=120 
51.6 (31.0)a 
n=275 
59.7 (28.6)a 
n=273 
Month 12 16.4 (28.5) 
n=94 
52.5 (29.7)a 
n=240 
61.7 (28.7)a 
n=230 
Activities: Mean change from baseline (SD) 
Month 6 18.9 (28.3) 
n=120 
39.8 (28.3)a 
n=275 
46.4 (27.5)a 
n=273 
Month 12 11.7 (27.0) 
n=94 
41.9 (27.7)a 
n=240 
48.9 (28.0)a 
n=230 
Energy/Mood: Mean change from baseline (SD) 
Month 6 20.2 (26.6) 
n=120 
33.7 (26.1)a 
n=275 
39.8 (26.5)a 
n=273 
Month 12 13.5 (25.6) 
n=94 
36.2 (25.1)a 
n=240 
42.0 (26.4)a 
n=230 
Control: Mean change from baseline (SD) 
Month 6 18.9 (26.8) 
n=120 
32.6 (27.8)a 
n=276 
38.0 (26.2)a 
n=273 
Month 12 12.9 (27.3) 
n=94 
33.8 (25.6)a 
n=240 
39.2 (26.5)a 
n=230 
Self-Conscious: Mean change from baseline (SD) 
Month 6 19.2 (30.0) 
n=120 
32.0 (29.2)a 
n=276 
42.1 (31.2)a 
n=273 
Month 12 16.3 (26.1) 
n=94 
35.1 (31.0)a 
n=240 
46.4 (32.0)a 
n=230 
Sexual function: Mean change from baseline (SD) 
Month 6 14.8 (34.3) 29.6 (36.1)a 32.1 (34.2)a 
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n=114 n=272 n=268 
Month 12 12.0 (38.7) 
n=92 
31.2 (34.7)a 
n=236 
36.0 (35.6)a 
n=226 
HRQL=health-related quality of life; mITT=modified intent-to-treat; UFS-QoL=Uterine Fibroid symptom and Health Related Quality 
of Life questionnaire. 
aP<0.001 statistically significant difference vs placebo analyzed using the Hochberg multiple comparison procedure with an initial 
critical P=0.05 (from the contrasts within the framework of the analysis of covariance model with baseline as a covariate and 
treatment as a fixed factor). 
Scores can range from 0 to 100. For symptom severity: 0=distressed not at all, 100=distressed a very great deal. For other subscales: 
0=Quality of life affected all of the time, 100=Quality of life affected none of the time. 
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Supplemental Table VIII. Change from Baseline in Leiomyoma Symptom Assessment Questionnaire Scores (mITT 
Population) 
 Study 1 and Study 2 
Symptom 
Placebo 
(n=149) 
Asoprisnil 10 mg 
(n=308) 
Asoprisnil 25 mg 
(n=306) 
Bloating: Mean change from baseline 
Month 2 −0.35 
n=149 
−0.62a 
n=307 
-0.79a 
n=306 
Month 4 −0.35 
n=137 
−0.73a 
n=295 
−0.87a 
n=290 
Month 6 −0.41 
n=120 
−0.77a 
n=278 
−0.99a 
n=271 
Month 12 −0.43 
n=93 
−0.81a 
n=239 
−1.03a 
n=235 
Pelvic pressure: Mean change from baseline 
Month 2 −0.40 
n=149 
−0.79a 
n=308 
−1.05a 
n=306 
Month 4 −0.45 
n=137 
−0.85a 
n=296 
−1.11a 
n=290 
Month 6 −0.43 
n=120 
−0.83a 
n=278 
−1.18a 
n=271 
Month 12 −0.46 
n=93 
−0.87a 
n=239 
−1.20a 
n=235 
Dysmenorrhea: Mean change from baseline 
Month 2 −0.50 
n=149 
−1.19a 
n=308 
−1.41a 
n=305 
Month 4 −0.50 
n=137 
−1.25a 
n=296 
−1.44a 
n=289 
Month 6 −0.54 
n=120 
−1.23a 
n=278 
−1.47a 
n=270 
Month 12 −0.45 −1.22a −1.43a 
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n=93 n=239 n=234 
mITT=modified intent-to-treat. 
aP<0.001 statistically significant difference vs placebo analyzed using the Hochberg multiple comparison procedure with an initial 
critical P=0.05 (from the generalized Cochran-Mantel-Haenszel mean score test with baseline scores as strata). 
Visit and baseline scores are from a 4-point grading scale: 0=None or not applicable; 1=Mild; 2=Moderate; 3=Severe.  
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Supplemental Table IX. Endometrial Biopsy Results at Baseline, Month 6, and Month 12 (Safety Analysis Set)  
 
 Study 1 and Study 2 
Diagnostic Category 
Diagnostic Subcategory 
Placebo 
n/N (%) 
Asoprisnil 10 mg 
n/N (%) 
Asoprisnil 25 mg 
n/N (%) 
Normal quiescent or minimally stimulated endometrium 
Atrophy    
Baseline 0/171 0/362 0/363 
Month 6 0/135 0/312 2/301 (1) 
Month 12 0/110 0/281 1/272 (<1) 
    
Inactive    
Baseline 2/171 (1) 1/362 (<1) 7/363 (2) 
Month 6 4/135 (3) 60/312 (19)a 60/301 (20)a 
Month 12 3/110 (3) 79/281 (28)a 88/272 (32)a 
Endometrial epithelium without intact 
glands and stroma 
   
Baseline 0/171 3/362 (1) 3/363 (1) 
Month 6 0/135 3/312 (1) 2/301 (1) 
Month 12 0/110 1/281 (<1) 2/272 (1) 
Inactive pattern with disordered 
glandular architecture 
   
Baseline 0/171 0/362 0/363 
Month 6 0/135 1/312 (<1) 0/301 
Month 12 0/110 2/281 (1) 2/272 (1) 
Inactive pattern with abundant stromal 
component 
   
Baseline 1/171 (1) 0/362 1/363 (<1) 
Month 6 0/135 3/312 (1) 5/301 (2) 
Month 12 0/110 12/281 (4)b 13/272 (5)b 
Category subtotal    
Baseline 3/171 (2) 4/362 (1) 11/363 (3) 
Month 6 4/135 (3) 67/312 (21)a 69/301 (23)a 
Month 12 3/110 (3) 94/281 (33)a 106/272 (39)a 
Normal secretory phase or non-physiologic secretory patterns 
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Cycling/physiologic    
Baseline 80/171 (47) 152/362 (42) 127/363 (35)c 
Month 6 34/135 (25) 11/312 (4)a 2/301 (1)a 
Month 12 35/110 (32) 13/281 (5)a 2/272 (1)a 
Non-physiologic secretory effect    
Baseline 3/171 (2) 8/362 (2) 23/363 (6)b 
Month 6 1/135 (1) 47/312 (15)a 58/301 (19)a 
Month 12 4/110 (4) 30/281 (11)b 21/272 (8) 
Secretory pattern, mixed type (mixed 
secretory and proliferative changes) 
   
Baseline 11/171 (6) 17/362 (5) 9/363 (2)b 
Month 6 5/135 (4) 42/312 (13)a 36/301 (12)c 
Month 12 3/110 (3) 23/281 (8) 30/272 (11)c 
Menstrual    
Baseline 1/171 (1) 4/362 (1) 3/363 (1) 
Month 6 4/135 0/312c 0/301c 
Month 12 2/110 (2) 1/281 (<1) 0/272 
Category subtotal    
Baseline 95/171 (56) 181/362 (50) 162/363 (45)b 
Month 6 44/135 (33) 100/312 (32) 96/301 (32) 
Month 12 44/110 (40) 67/281 (24)c 53/272 (19)a 
Proliferative phase or non-physiologic proliferative endometrium 
Weakly proliferative    
Baseline 10/171 (6) 14/362 (4) 17/363 (5) 
Month 6 9/135 (7) 58/312 (19)a 51/301 (17)c 
Month 12 0/110 34/281 (12)a 25/272 (9)a 
Mild to strongly proliferative patterns 
(active proliferation) 
   
Baseline 51/171 (30) 120/362 (33) 137/363 (38) 
Month 6 52/135 (39) 34/312 (11)a 10/301 (3)a 
Month 12 43/110 (39) 19/281 (7)a 7/272 (3)a 
Proliferative pattern with dominant 
breakdown/stromal collapse 
   
Baseline 5/171 (3) 23/362 (6) 15/363 (4) 
Month 6 11/135 (8) 3/312 (1)a 2/301 (1)a 
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Month 12 4/110 (4) 1/281 (<1)b 3/272 (1) 
Disordered proliferative pattern    
Baseline 1/171 (1) 1/362 (<1) 3/363 (1) 
Month 6 2/135 (1) 10/312 (3) 14/301 (5) 
Month 12 0/110 6/281 (2) 8/272 (3) 
Category subtotal    
Baseline 67/171 (39) 158/362 (44) 172/363 (47) 
Month 6 74/135 (55) 105/312 (34)a 77/301 (26)a 
Month 12 47/110 (43) 60/281 (21)a 43/272 (16)a 
Reactive and inflammatory states (endometritis, infections, metaplasia) 
Endometritis, acute    
Baseline 1/171 (1) 0/362  0/363 
Month 6 0/135 1/312 (<1) 0/301 
Month 12 0/110 1/281 (<1) 0/272 
Endometritis, chronic    
Baseline 0/171 3/362 (1) 5/363 (1) 
Month 6 0/135 2/312 (1) 0/301 
Month 12 1/110 (1) 1/281 (<1) 2/272 (1) 
Endometritis, granulomatous    
Baseline 0/171 0/362 0/363 
Month 6 0/135 0/312 0/301 
Month 12 0/110 0/281 0/272 
Epithelial metaplasia, ciliated (tubal) 
type 
   
Baseline 1/171 (1) 0/362 0/363 
Month 6 0/135 0/312 0/301 
Month 12 0/110 0/281 0/272 
Epithelial metaplasia, ciliated and 
eosinophilic types 
   
Baseline 1/171 (1) 0/362  3/363 (1) 
Month 6 0/135 0/312 0/301 
Month 12 0/110 0/281 0/272 
Category subtotal    
Baseline 3/171 (2) 3/362 (1) 8/363 (2) 
Month 6 0/135 3/312 (1) 0/301 
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Month 12 1/110 (1) 2/281 (1) 2/272 (1) 
Polyp (Uterine) 
Endometrial polyp, atrophic type    
Baseline 0/171 0/362 0/363 
Month 6 0/135 1/312 (<1) 0/301 
Month 12 0/110 1/281 (<1) 0/272 
Endometrial polyp, functional type    
Baseline 0/171 2/362 (1) 0/363 
Month 6 0/135 3/312 (1) 1/301 (<1) 
Month 12 0/110 0/281 2/272 (1) 
Endometrial polyp, hyperplastic type    
Baseline 0/171 0/362 0/363 
Month 6 0/135 0/312 1/301 (<1) 
Month 12 0/110 1/281 (<1) 1/272 (<1) 
Endometrial polyp, not otherwise 
specified 
   
Baseline 0/171 1/362 (<1) 0/363 
Month 6 0/135 1/312 (<1) 4/301 (1) 
Month 12 0/110 3/281 (1) 4/272 (1) 
Category subtotal    
Baseline 0/171 3/362 (1) 0/363 
Month 6 0/135 5/312 (2) 6/301 (2) 
Month 12 0/110 5/281 (2) 7/272 (3) 
Endometrial hyperplasia 
Complex hyperplasia (no atypia)    
Baseline 0/171 0/362 0/363 
Month 6 0/135 1/312 (<1) 0/301 
Month 12 0/110 0/281 0/272 
Endometrial benign tumor or cervical disease including dysplasias/CIS 
Baseline 0/171 0/362 0/363 
Month 6 0/135 0/312 1/301 (<1) 
Month 12 0/110 2/281 (1) 0/272 
Endometrial and other malignancies 
Baseline 0/171 0/362 0/363 
Month 6 0/135 0/312 1/301 (<1) 
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Month 12 0/110 0/281 0/272 
Unsatisfactory tissue for diagnosis 
Baseline 3/171 (2) 13/362 (4) 10/363 (3) 
Month 6 12/135 (9) 31/312 (10) 51/301 (17)b 
Month 12 15/110 (14) 51/281 (18) 61/272 (22) 
P values are from Fisher exact test. Patients could have findings in more than 1 category. 
aP≤0.001 vs placebo. 
bP≤0.05 vs placebo. 
cP≤0.01 vs placebo. 
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Supplemental Table X. Endometrial Thickness by TVU (Safety Analysis Set) 
 Study 1 and Study 2 
Parameter 
Placebo 
(n=173) 
Asoprisnil 
10 mg 
(n=370) 
Asoprisnil 
25 mg 
(n=364) 
Baseline endometrial thickness, 
mean (SD), mm 
8.6 (4.0) 
n=154 
8.4 (4.2) 
n=331 
8.8 (4.5) 
n=323 
Visit endometrial thickness, 
mean (SD), mm 
   
   Month 4 8.0 (3.6) 
n=123 
8.0 (4.6) 
n=279 
7.8 (4.5) 
n=265 
   Month 8 8.4 (4.5) 
n=108 
9.3 (6.3) 
n=260 
9.4 (6.6) 
n=257 
TVU=transvaginal ultrasound. 
Each dose of asoprisnil was tested versus placebo for change from baseline, and there were no statistically significant differences 
based on a pairwise comparison from contrasts within the framework of the 1-way analysis of variance model. 
  
 
 
65 
 
Supplemental Table XI. Endometrial Thickness by MRI (Safety Analysis Set) 
 Study 1 and Study 2 
Parameter 
Placebo 
(n=173) 
Asoprisnil 
10 mg 
(n=370) 
Asoprisnil 
25 mg 
(n=364) 
Baseline endometrial thickness, 
mean (SD), mm 
7.8 (4.1) 
n=173 
7.5 (3.7) 
n=366 
8.0 (4.4) 
n=363 
Visit endometrial thickness, 
mean (SD), mm 
   
   Month 6 6.8 (3.3) 
n=139 
7.1 (4.6) 
n=311 
7.4 (6.5) 
n=304 
   Month 12 6.9 (3.0) 
n=104 
9.6 (8.7)a 
n=274 
9.7 (8.2)a 
n=256 
MRI=magnetic resonance imaging. 
aP<0.01 vs placebo for change from baseline (pairwise comparison from contrasts within the framework of the 1-way analysis of 
variance model). 
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Supplemental Table XII. Endometrial Texture by MRI Images (All Participants With Follow-Up Data) 
 Study 1 and Study 2 
Diagnosis 
Placebo 
n=25 
n/N (%) 
Asoprisnil 10 mg 
n=61 
n/N (%) 
Asoprisnil 25 mg 
n=59 
n/N (%) 
Endometrial cysts 
Screening 0/25 0/60 0/59 
Month 6 0/18 4/52 (8) 5/46 (11) 
Month 12 0/10 6/45 (13) 7/33 (21) 
Follow-up month 6 0/19 1/42 (2) 0/37 
Subendometrial cysts 
Screening 3/25 (12) 4/60 (7) 7/59 (12) 
Month 6 1/18 (6) 5/52 (10) 2/46 (4) 
Month 12 1/10 (10) 7/45 (16) 2/33 (6) 
Follow-up month 6 1/19 (5) 2/42 (5) 1/37 (3) 
Endometrial heterogeneity suggestive of polyp 
Screening 0/25 0/60 0/59 
Month 6 0/18 3/52 (6) 5/46 (11) 
Month 12 0/10 8/45 (18) 7/33 (21) 
Follow-up month 6 0/19 1/42 (2) 0/37 
    
Endometrial heterogeneity suggestive of polyp or cyst 
Screening 0/25 0/60 0/59 
Month 6 0/18 4/52 (8) 6/46 (13) 
Month 12 0/10 9/45 (20) 7/33 (21) 
Follow-up month 6 0/19 1/42 (2) 0/37 
MRI=magnetic resonance imaging.  
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Supplemental Table XIII. Mean Serum Lipids at Baseline and 6 and 12 Months (All Participants) 
 Study 1 Study 2 
Lipid Placebo 
(n=87) 
Asoprisnil 
10 mg 
(n=196) 
Asoprisnil 
25 mg 
(n=192) 
Placebo 
(n=86) 
Asoprisnil 
10 mg 
(n=174) 
Asoprisnil 
25 mg 
(n=172) 
Total Cholesterol, mg/dL 
Baseline, mean 
(SD) 
188.4 (40.1) 
n=85 
190.2 (33.6) 
n=189 
188.5 (34.9) 
n=189 
193.7 (35.5) 
n=82 
185.8 (34.4) 
n=171 
184.1 (29.4) 
n=164 
Month 6, mean 
(SD) 
194.1 (41.5) 
n=67 
191.9 (33.2) 
n=163 
186.7 (32.7) 
n=161 
205.4 (40.8) 
n=60 
190.6 (30.7) 
n=138 
183.2 (28.7)a 
n=135 
Month 12, mean 
(SD) 
196.0 (37.8) 
n=56 
196.5 (34.1) 
n=131 
194.1 (36.3) 
n=138 
200.6 (34.1) 
n=43 
195.9 (31.6) 
n=118 
190.9 (28.8) 
n=110 
HDL, mg/dL 
Baseline, mean 
(SD) 
55.4 (14.7) 
n=85 
56.3 (15.7) 
n=189 
55.7 (14.2) 
n=189 
55.8 (13.1) 
n=82 
55.8 (13.9) 
n=170 
56.8 (14.7) 
n=164 
Month 6, mean 
(SD) 
56.1 (15.4) 
n=67 
54.1 (14.9)b 
n=163 
50.3 (13.6)b 
n=161 
56.1 (11.1) 
n=60 
53.3 (12.4)a 
n=137 
50.4 (12.8)b 
n=135 
Month 12, mean 
(SD) 
54.4 (12.3) 
n=56 
52.3 (15.0)c 
n=131 
47.2 (12.5)b 
n=138 
54.9 (11.9) 
n=43 
50.9 (12.3)c 
n=118 
48.0 (12.6)b 
n=110 
LDL, mg/dL 
Baseline, mean 
(SD) 
112.5 (37.0) 
n=85 
110.5 (28.6) 
n=186 
110.2 (31.1) 
n=188 
113.9 (32.1) 
n=81 
108.1 (31.5) 
n=169 
105.7 (26.9) 
n=164 
Month 6, mean 
(SD) 
117.3 (38.9) 
n=66 
116.9 (30.6) 
n=162 
117.1 (29.3)d 
n=161 
129.1 (38.4) 
n=60 
115.9 (28.1) 
n=137 
112.8 (27.2) 
n=135 
Month 12, mean 
(SD) 
121.7 (33.3) 
n=56 
123.6 (29.4) 
n=130 
125.5 (31.5)d 
n=136 
126.6 (30.9) 
n=43 
122.6 (30.2) 
n=118 
122.9 (25.9) 
n=110 
Triglyceride, mg/dL 
Baseline, mean 
(SD) 
102.8 (57.4) 
n=85 
121.3 (84.0) 
n=189 
114.2 (74.9) 
n=189 
118.4 (84.5) 
n=82 
112.7 (76.5) 
n=171 
108.1 (66.7) 
n=164 
Month 6, mean 
(SD) 
103.1 (78.1) 
n=67 
105.0 (58.9) 
n=163 
96.2 (51.8)d 
n=161 
100.7 (48.7) 
n=60 
108.1 (67.0) 
n=138 
99.9 (60.1) 
n=135 
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Month 12, mean 
(SD) 
99.6 (54.5) 
n=56 
102.5 (61.0) 
n=131 
102.6 (68.2) 
n=138 
95.7 (47.6) 
n=43 
112.1 (63.6)a 
n=118 
99.6 (51.2) 
n=110 
HDL=high-density lipoprotein; LDL=low-density lipoprotein. 
P values derived from pairwise contrasts within the framework of a 1-way analysis of variance model. 
aP<0.005, relative to placebo for change from baseline. 
bP<0.001, relative to placebo for change from baseline. 
cP<0.01, relative to placebo for change from baseline. 
dP<0.05, relative to placebo for change from baseline. 
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Supplemental Table XIV. Mean Hormone and SHBG at Baseline and 6 and 12 Months (All Participants) 
 Study 1 Study 2 
Hormone Placebo 
(n=87) 
Asoprisnil 
10 mg 
(n=196) 
Asoprisnil 
25 mg 
(n=192) 
Placebo 
(n=87) 
Asoprisnil 
10 mg 
(n=196) 
Asoprisnil 
25 mg 
(n=192) 
Thyroxine (T4), μg/dL 
Baseline, mean 
(SD) 
7.9 (1.1) 
n=85 
7.8 (1.3) 
n=189 
8.0 (1.5) 
n=185 
7.6 (1.3) 
n=81 
8.0 (1.4) 
n=170 
7.8 (1.4) 
n=163 
Month 6, mean 
(SD) 
7.9 (1.2) 
n=67 
7.4 (1.4)a 
n=160 
7.2 (1.3)b 
n=160 
7.7 (1.7) 
n=60 
7.6 (1.3)c 
n=138 
7.4 (1.3)a 
n=134 
Month 12, mean 
(SD) 
7.7 (1.1) 
n=56 
7.4 (1.4) 
n=131 
7.3 (1.4)c 
n=138 
7.6 (1.7) 
n=43 
7.6 (1.4) 
n=118 
7.4 (1.3) 
n=110 
TSH, μIU/mL 
Baseline, mean 
(SD) 
1.8 (1.3) 
n=85 
1.8 (1.2) 
n=189 
1.8 (1.31) 
n=186 
2.0 (2.7) 
n=82 
1.8 (1.8) 
n=171 
1.7 (1.2) 
n=163 
Month 6, mean 
(SD) 
1.8 (1.3) 
n=67 
1.9 (1.5) 
n=161 
1.9 (1.4) 
n=161 
1.8 (1.5) 
n=60 
1.6 (0.9) 
n=138 
1.9 (2.1) 
n=134 
Month 12, mean 
(SD) 
2.0 (2.2) 
n=56 
1.8 (1.4) 
n=131 
2.0 (1.5) 
n=139 
2.2 (2.2) 
n=43 
1.8 (1.7) 
n=118 
1.9 (1.5) 
n=110 
Cortisol, μg/dL 
Baseline, mean 
(SD) 
11.8 (4.9) 
n=86 
11.0 (4.9) 
n=195 
11.2 (4.9) 
n=181 
11.8 (5.4) 
n=84 
12.3 (4.9) 
n=174 
11.8 (5.1) 
n=172 
Month 12, mean 
(SD) 
10.5 (4.3) 
n=56 
9.9 (4.1) 
n=131 
9.2 (4.0)c 
n=139 
10.7 (4.2) 
n=43 
9.8 (4.2) 
n=117 
10.1 (4.4) 
n=111 
DHEA-S, μg/dL 
Baseline, mean 
(SD) 
79.7 (43.0) 
n=84 
80.2 (45.7) 
n=189 
76.7 (44.7) 
n=188 
72.2 (36.5) 
n=82 
85.4 (45.6) 
n=171 
82.6 (47.4) 
n=164 
Month 12, mean 
(SD) 
70.6 (35.8) 
n=56 
76.0 (42.3) 
n=134 
73.9 (40.9)c 
n=143 
71.4 (40.0) 
n=44 
84.8 (47.2) 
n=120 
82.6 (44.4) 
n=113 
Prolactin, ng/mL 
Baseline, mean 
(SD) 
15.3 (8.3) 
n=85 
15.2 (9.5) 
n=189 
15.4 (9.0) 
n=185 
16.0 (13.6) 
n=81 
15.9 (8.6) 
n=170 
15.3 (7.8) 
n=163 
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Month 6, mean 
(SD) 
16.5 (7.7) 
n=67 
16.7 (12.3) 
n=161 
13.6 (7.7)d 
n=160 
16.3 (13.0) 
n=60 
15.2 (9.1) 
n=138 
14.0 (8.0) 
n=135 
Month 12, mean 
(SD) 
17.2 (8.7) 
n=56 
15.2 (9.2) 
n=131 
12.4 (6.3)b 
n=138 
19.9 (11.3) 
n=43 
15.5 (8.3)b 
n=118 
12.7 (8.0)b 
n=110 
FSH, mIU/mL 
Baseline, mean 
(SD) 
9.7 (5.7) 
n=85 
11.4 (7.4) 
n=190 
9.8 (6.1) 
n=187 
9.2 (7.5) 
n=82 
9.4 (5.8) 
n=171 
11.8 (9.0) 
n=164 
Month 6, mean 
(SD) 
9.4 (10.2) 
n=67 
7.2 (6.9)b 
n=163 
6.5 (5.2)a 
n=161 
8.8 (8.3) 
n=60 
7.3 (10.1) 
n=139 
5.9 (3.6)b 
n=134 
Month 12, mean 
(SD) 
9.6 (12.6) 
n=56 
9.1 (11.3) 
n=131 
6.9 (6.9) 
n=139 
5.8 (3.6) 
n=43 
8.3 (11.5) 
n=118 
7.2 (6.5) 
n=111 
Luteinizing Hormone, mIU/mL 
Baseline, mean 
(SD) 
5.5 (4.2) 
n=85 
5.7 (4.7) 
n=190 
5.1 (4.0) 
n=187 
5.1 (6.0) 
n=82 
5.3 (3.9) 
n=171 
6.6 (8.7) 
n=164 
Month 6, mean 
(SD) 
10.7 (13.1) 
n=67 
7.1 (9.2)d 
n=163 
5.6 (4.5)d 
n=161 
9.6 (13.0) 
n=60 
8.2 (16.6) 
n=139 
6.1 (5.0)c 
n=134 
Month 12, mean 
(SD) 
10.1 (12.2) 
n=55 
7.6 (8.8)c 
n=129 
5.4 (4.7)a 
n=137 
7.9 (10.2) 
n=43 
7.3 (8.4) 
n=117 
5.8 (4.0)c 
n=110 
Total Testosterone, ng/dL  
Baseline, mean 
(SD) 
21.1 (8.9) 
n=84 
19.2 (7.8) 
n=189 
20.1 (7.4) 
n=188 
21.1 (10.6) 
n=81 
22.7 (9.5) 
n=170 
20.8 (9.8) 
n=165 
Month 6, mean 
(SD) 
28.3 (17.0) 
n=67 
21.9 (8.7)b 
n=164 
19.3 (8.0)b 
n=162 
27.8 (14.6) 
n=60 
23.1 (11.0)b 
n=138 
19.0 (7.9)b 
n=137 
Month 12, mean 
(SD) 
28.8 (19.2) 
n=57 
20.7 (7.9)b 
n=134 
18.6 (7.5)b 
n=143 
28.9 (14.3) 
n=44 
22.9 (11.0)b 
n=120 
19.1 (7.6)b 
n=113 
Androstenedione, ng/dL 
Baseline, mean 
(SD) 
90.5 (34.1) 
n=84 
81.8 (32.0) 
n=191 
85.9 (33.6) 
n=186 
87.3 (32.7) 
n=83 
94.8 (36.8) 
n=170 
89.6 (35.8) 
n=165 
Month 6, mean 
(SD) 
103.3 (47.3) 
n=67 
96.5 (30.1) 
n=164 
91.2 (36.4) 
n=162 
107.4 (47.1) 
n=59 
101.7 (43.0)c 
n=139 
91.8 (36.2)c 
n=136 
Month 12, mean 
(SD) 
99.5 (41.4) 
n=57 
89.5 (30.6) 
n=135 
84.8 (38.0) 
n=142 
112.5 (44.7) 
n=44 
97.6 (37.3)d 
n=121 
93.1 (37.8)d 
n=113 
SHBG, nmol/L 
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Baseline, mean 
(SD) 
92.5 (43.8) 
n=84 
88.1 (41.4) 
n=190 
91.7 (45.5) 
n=188 
87.6 (42.5) 
n=81 
94.2 (48.7) 
n=170 
95.0 (53.1) 
n=165 
Month 6, mean 
(SD) 
98.2 (52.3) 
n=67 
68.8 (38.7)b 
n=165 
50.8 (24.5)b 
n=162 
84.2 (36.5) 
n=60 
68.0 (34.7)b 
n=139 
51.1 (28.8)b 
n=137 
Month 12, mean 
(SD) 
96.4 (50.0) 
n=57 
69.8 (36.4)b 
n=134 
50.0 (26.4)b 
n=143 
85.1(39.5) 
n=44 
65.9 (32.6)b 
n=121 
50.3 (26.8)b 
n=113 
DHEA-S=dehydroepiandrosterone sulfate; FSH=follicle-stimulating hormone; SHBG=sex hormone binding globulin; TSH=thyroid-stimulating hormone. 
P values derived from pairwise contrasts within the framework of a 1-way analysis of variance model. 
aP<0.01, relative to placebo for change from baseline. 
bP<0.001, relative to placebo for change from baseline. 
cP<0.05, relative to placebo for change from baseline. 
dP<0.005, relative to placebo for change from baseline. 
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Supplemental Figure Legends 
Supplemental Figure 1. Mean number of days with spotting or bleeding (intent-to-treat 
population). BL=baseline. Error bars represent 2 × the standard error of the mean. *P<0.001 
statistically significant difference for asoprisnil 10 mg or 25 mg vs placebo for change from 
baseline using the Hochberg multiple comparison procedure with an initial critical P=0.05 (from 
the Fisher exact test). 
Supplemental Figure 2. Mean estradiol (E2) values over time (all participants). LLN=lower 
limit of normal; ULN=upper limit of normal. *P<0.001, **P<0.01, and ***P<0.05 vs placebo 
for change from baseline (pairwise comparison from contrasts within the framework of the 1-
way analysis of variance model). Error bars represent 2 × the standard error of the mean. 
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Supplemental Figure 1. 
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Supplemental Figure 2. 
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